There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.
I spent the weekend with thousands of blood disease researchers. This is what happened.
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "perilous reversal" (up big yesterday but down big today) candidate